Cantabio Pharmaceuticals Inc. (CTBO)

[TanMan7272]

UPDATE -- Cantabio Pharmaceuticals and University of Antioquia Collaborate to Research Company's Therapeutic Candidates Targeting DJ-1 Protein to Treat Parkinson's DiseaseThursday 06/16/2016 09:46 AM ET - GlobeNewsWire via Dow Jones News
UPDATE -- Cantabio Pharmaceuticals and University of Antioquia Collaborate to Research Company's Therapeutic Candidates Targeting DJ-1 Protein to Treat Parkinson's Disease SAN FRANCISCO, June 16, 2016 (GLOBE NEWSWIRE) -- Cantabio Pharmaceuticals, Inc. (OTCQB:CTBO) today announced its collaboration with the Neuroscience Research Group at the University of Antioquia in Colombia, to further evaluate the company's DJ-1 protein-targeting small molecule pharmaceutical chaperone drug candidates in development for the treatment of Parkinson's disease (PD). The partnership brings together Cantabio's novel approach and the University of Antioquia's research excellence on the role of oxidative stress in PD and other neurodegenerative diseases.